▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / KKRS

KKRS — KKR & Co. Inc.

—
NYSE · Financials · Capital Markets · CIK 1404912 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited operates as a subsidiary of Stellar Infinity Company Ltd.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2024 4,791,696,000 4,791,696,000 4,607,028,000 600,550,000 360,099,411,000 — 298,114,719,000
Dec 2023 3,315,481,000 3,315,481,000 — 1,490,126,000 317,294,194,000 — 258,915,282,000
Dec 2022 1,856,432,000 1,856,432,000 2,247,952,000 49,887,000 275,346,636,000 — 219,975,946,000
Jun 2021 3,136,181,000 3,136,181,000 3,401,237,000 1,315,275,000 229,234,863,000 — 176,828,101,000

Annual Trend (SEC EDGAR, last 9y)

Revenues vs Net Income (last 9y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 14,499,312,000 13,812,541,000 3,732,261,000 360,099,411,000 298,114,719,000 — —
Dec 2023 5,704,180,000 4,609,782,000 -521,664,000 317,294,194,000 258,915,282,000 — —
Dec 2022 16,226,040,000 16,379,725,000 4,732,406,000 275,346,636,000 219,975,946,000 — —
Dec 2019 2,395,836,000 1,506,088,000 1,131,063,000 60,899,319,000 30,396,945,000 — —
Dec 2018 472,606,000 — 178,443,000 50,743,375,000 25,360,766,000 — —
Dec 2016 767,755,000 — 267,684,000 39,002,897,000 21,884,814,000 — —
Dec 2015 — — 270,507,000 71,042,339,000 21,574,754,000 — —
Dec 2014 — — 210,041,000 65,872,745,000 14,168,684,000 — —
4,230,891,000 4,938,158,000 2,002,509,000 — — — —

TTM Snapshot

Revenues TTM
$13,099,790,000
NetIncome TTM
$3,455,838,000
OpCashFlow TTM
$0
Assets (Latest)
$360,099,411,000
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
MS MORGAN STANLEY $350.60B $222.28 —
GS GOLDMAN SACHS GROUP INC $311.29B $1055.18 —
SCHW SCHWAB CHARLES CORP $179.34B $103.12 —
BLK BlackRock, Inc. $160.59B $1036.11 —
GLD SPDR GOLD TRUST $98.14B $377.01 —

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →